XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis

Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer

(2012) Hongying Lv et al.   PATHOLOGY & ONCOLOGY RESEARCH

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

(2011) Ming Yin et al.   CLINICAL CANCER RESEARCH

Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer

(2011) Maria J Lamas et al.   PHARMACOGENOMICS

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

(2010) Junshik Hong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy

(2010) Ming-Yii Huang et al.   Pharmacogenetics and Genomics

Pharmacogenetics in chemotherapy of colorectal cancer

(2009) Lieke Henriette Tanja et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

(2009) W Chua et al.   BRITISH JOURNAL OF CANCER

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer

(2009) Jun Liang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Influence ofGSTP1I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

(2009) Yen-Chung Chen et al.   CANCER SCIENCE

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

(2008) L Paré et al.   BRITISH JOURNAL OF CANCER

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer

(2008) Eva Martinez-Balibrea et al.   EUROPEAN JOURNAL OF CANCER